New drug LY3451838 put through safety checks in healthy people
NCT ID NCT03692949
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This early-stage trial tested the safety of a new drug called LY3451838 in 53 healthy adults. Researchers gave the drug either into a vein or under the skin to see how the body handles it and whether it causes side effects. Since participants were healthy, the study was not designed to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3451838
What could go wrong
This is an early safety study in healthy people, so it won't show if the drug works for any disease. The drug may cause side effects or fail in later trials.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.